The BIRCH trial data discussed by Dr Peters
NSCLC: the increasing need for PD-L1 testing
Maximizing treatment benefits in NSCLC
What is durvalumab’s future as a treatment option in lung cancer?
NSCLC: identifying patients most likely to relapse